spec sheet11 rows
5α-Dihydroprogesterone (5α-DHP) is an endogenous neurosteroid and progestogen formed when the enzyme 5α-reductase reduces progesterone at the A-ring of the steroid nucleus, yielding 5α-pregnane-3,20-dione. It occupies the committed first step of the principal neurosteroid pathway, standing between progesterone and allopregnanolone (its 3α-hydroxylated metabolite and one of the most potent naturally occurring positive modulators of the GABA-A receptor, the brain's main inhibitory ion channel). Unlike allopregnanolone, 5α-DHP is itself a high-affinity agonist of the classical (nuclear) progesterone receptor, driving progesterone-responsive gene transcription; in horses it is a fully biopotent progesterone receptor agonist that sustains the second half of pregnancy after circulating progesterone becomes undetectable. It is synthesized in situ within neurons and glia of the central and peripheral nervous systems, where its production rises after nerve injury and falls under chronic stress.
- Acts as a genuine progesterone-receptor agonist, driving progesterone-responsive gene transcription in nervous and reproductive tissue
- Serves as the committed precursor to allopregnanolone, the potent GABA-A positive modulator that underlies much of progesterone's calming, anxiolytic and anticonvulsant activity
- Rises locally after nerve injury as part of an apparent endogenous neuroprotective response
- Supports peripheral myelin in rodent models, upregulating the myelin proteins P0 and PMP22 and reducing myelin abnormalities in aged and diabetic peripheral nerves
- Sustains pregnancy through the progesterone receptor, definitively shown in horses and plausibly relevant to humans
- Participates, together with allopregnanolone, in reproductive-axis signaling and the neural control of female sexual behavior
- Promotes proliferation and metastatic behavior of breast cancer cells in laboratory models, independent of classical hormone-receptor status
- Elevated circulating levels are associated with depression in late pregnancy (association, not proven cause)
- As a potent progestogen, exogenous exposure would be expected to carry systemic progestational effects
- Brain levels fall under chronic stress and social isolation, a change linked to emotional and cognitive dysfunction in animal models
Overview
The pivotal branch point of the neurosteroid pathway; a genuine progesterone-receptor agonist in its own right and the obligatory precursor to allopregnanolone.
- In pregnant mares, circulating progesterone falls to undetectable levels in the second half of gestation, and 5α-DHP takes over as the progesterone-receptor agonist that keeps the pregnancy going; it activates the equine progesterone receptor as potently as progesterone itself.
- 5α-DHP is the transcriptionally active neurosteroid of its family: allopregnanolone has to be oxidized back into 5α-DHP before it can switch on any progesterone-receptor-controlled genes.
- The brain enzyme that oxidizes allopregnanolone back to 5α-DHP, 17β-hydroxysteroid dehydrogenase type 10, is a mitochondrial protein also studied for its interaction with amyloid-beta in Alzheimer's disease.
- Human plasma 5α-DHP climbs during pregnancy and is significantly higher in women who are depressed in the second half of pregnancy than in non-depressed controls.
Mechanism
5α-Dihydroprogesterone is generated by reduction of the 4,5 double bond of progesterone by steroid 5α-reductase (both the type I and type II isozymes catalyze this step). It is the obligatory intermediate of the canonical neurosteroid cascade: 3α-hydroxysteroid dehydrogenase (3α-HSD; in humans the aldo-keto reductase AKR1C2, also called type III 3α-HSD) then reduces the 3-keto group of 5α-DHP to give allopregnanolone (3α-hydroxy-5α-pregnan-20-one). This final step is readily reversible; a brain 17β-hydroxysteroid dehydrogenase type 10 and 3α-HSD can oxidize allopregnanolone back to 5α-DHP, so the two steroids are held in a dynamic equilibrium that governs how much (inhibitory) tone the pathway ultimately delivers.
The defining pharmacology of 5α-DHP is its direct agonism of the classical intracellular (nuclear) progesterone receptor, a -activated transcription factor. Rupprecht and colleagues demonstrated that 3α-hydroxylated neurosteroids such as allopregnanolone are essentially silent at the progesterone receptor and must first be oxidized back to a 5α-pregnane (3-keto) steroid such as 5α-DHP before DNA binding and transcriptional activation can occur; 5α-DHP is therefore the transcriptionally active member of this steroid family. Its affinity for the progesterone receptor approaches that of progesterone itself; in the horse it activates the equine receptor as potently as progesterone and engages the human receptor strongly enough to support gestation.
Beyond the nuclear receptor, 5α-DHP acts at high-affinity, stereospecific plasma-membrane binding sites (a putative membrane 5αP receptor) that couple to the Ras/Raf/MEK/ERK1/2 mitogen-activated protein kinase (MAPK) cascade; in breast epithelium this rapid, nongenomic signaling promotes proliferation and loss of adhesion independently of classical progesterone or receptor status. By contrast, 5α-DHP has little direct activity at the -A receptor, because a 3α-hydroxyl group is an absolute structural requirement for positive modulation of that channel; its influence on inhibitory neurotransmission is thus indirect, exerted through conversion to allopregnanolone.
The steroid is made locally in the nervous system: 5α-reductase type I and 3α-HSD colocalize in cortical, hippocampal and olfactory-bulb principal neurons and in principal output neurons (striatal medium spiny, reticular thalamic and cerebellar Purkinje cells) rather than in or interneurons. -reuptake inhibitors such as fluoxetine and its norfluoxetine also act on this pathway, favoring the 3α-HSD-catalyzed conversion of 5α-DHP to allopregnanolone and raising brain allopregnanolone at concentrations below those needed to block serotonin reuptake.
receptor fingerprint
Progesterone receptor (nuclear)Agonist
Membrane progesterone (5αP) receptorAgonist
Anterior pituitary progestin receptorsAgonist
-A receptorIndirect potentiation via conversion to allopregnanolone
Safetyrisks and cautions, not medical advice
As an endogenous steroid, 5α-DHP is present throughout life and rises markedly in the luteal phase and in pregnancy, when its plasma concentration reaches roughly 12 to 40 percent that of progesterone. It is not marketed or established as a human therapeutic, and no validated dosing exists. The principal safety signal in the literature is oncological rather than neurological: tumorous human breast tissue preferentially converts progesterone to 5α-pregnanes, and 5α-DHP behaves as a mitogen and pro-metastatic factor in breast cell models, stimulating proliferation and detachment through membrane-receptor and MAPK signaling regardless of classical hormone-receptor status.
Observational data also link higher circulating 5α-DHP to depressive symptoms during the second half of pregnancy, although causation is unproven. Because it is a bona fide progesterone-receptor agonist, any exogenous use would be expected to carry the systemic effects of a potent progestogen. These considerations place 5α-DHP firmly in the domain of research and physiology rather than supplementation.
History
Interest in 5α-DHP grew out of mid-twentieth-century work on progesterone metabolism. In the 1970s and 1980s Karavolas and colleagues showed that the hypothalamus and pituitary actively convert progesterone to 5α-DHP and characterized the responsible progesterone 5α-reductase, linking the metabolite to gonadotropin regulation. Nuclear binding studies in the 1980s established that 5α-DHP occupies pituitary progestin receptors.
A conceptual turning point came in 1993, when Rupprecht and coworkers showed that the gene-regulating actions attributed to neurosteroids actually require their oxidation to 5α-pregnanes such as 5α-DHP, identifying it as the genomically active member of the family. From 2001 onward the Costa and Guidotti laboratory tied brain 5α-DHP and allopregnanolone to stress and psychiatric models, while John Wiebe's group defined its unexpected role as a breast-cancer promoter. In 2014 a landmark study of equine pregnancy demonstrated that 5α-DHP alone can maintain gestation, cementing its status as a second endogenous biopotent progesterone-receptor agonist.
Reputation
Within neuroendocrinology 5α-DHP is regarded as a linchpin of neurosteroidogenesis, yet it is far less famous than its downstream metabolite allopregnanolone, which has reached the clinic as the postpartum-depression drug brexanolone. In nootropic and biohacking circles 5α-DHP is a specialist curiosity rather than a supplement; discussion usually frames it as the progesterone-derived progestogen that carries the pathway's genomic (progesterone-receptor) signaling, in contrast to allopregnanolone's membrane (GABA-A) signaling.
Researchers are careful to distinguish it from the 5β isomer (5β-dihydroprogesterone, a uterine-quiescence factor) and from 3α-dihydroprogesterone, cousins with quite different activities. Its reputation is therefore twofold: a respected mechanistic hub in the nervous system and a cautionary example of how a physiological progesterone metabolite can promote tumor growth in the breast.
Subjective profileweighing the evidence above
Not a supplement, and the oncology signal is why: tumorous breast tissue preferentially makes it, and it drives breast cancer cell proliferation in laboratory models. Worth understanding as the committed step toward allopregnanolone, not worth dosing; there is no established human protocol anyway.
Resources
This entry is here for reference.
Research
- 1977first citedEffect of progesterone and its 5alpha-reduced metabolites on gonadotropin levels in estrogen-pr…
- 2001most active year5 papers
- 2016most recentMechanism of action of the breast cancer-promoter hormone, 5α-dihydroprogesterone (5αP), involv…
- 1.Pregnancy without progesterone in horses defines a second endogenous biopotent progesterone receptor agonist, 5α-dihydroprogesterone
- 2.Progesterone receptor-mediated effects of neuroactive steroids
- 3.Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation
- 4.Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis
- 5.Type 10 17beta-hydroxysteroid dehydrogenase catalyzing the oxidation of steroid modulators of gamma-aminobutyric acid type A receptors
- 6.Kinetics of allopregnanolone formation catalyzed by human 3alpha-hydroxysteroid dehydrogenase type III (AKR1C2)
- 7.Binding of 5alpha-dihydroprogesterone and other progestins to female rat anterior pituitary nuclear extracts
- 8.Mechanism of action of the breast cancer-promoter hormone, 5α-dihydroprogesterone (5αP), involves plasma membrane-associated receptors and MAPK activation
- 9.Plasma membrane receptors for the cancer-regulating progesterone metabolites 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-4-pregnen-20-one in MCF-7 breast cancer cells
- 10.Membrane 5alpha-pregnane-3,20-dione (5alphaP) receptors in MCF-7 and MCF-10A breast cancer cells are up-regulated by estradiol and 5alphaP and down-regulated by the progesterone metabolites, 3alpha-dihydroprogesterone and 20alpha-dihydroprogesterone, with associated changes in cell proliferation and detachment.
- 11.The endogenous progesterone metabolite, 5a-pregnane-3,20-dione, decreases cell-substrate attachment, adhesion plaques, vinculin expression, and polymerized F-actin in MCF-7 breast cancer cells.
- 12.Progesterone and its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin fiber morphological abnormalities and myelin fiber loss in the sciatic nerve of aged rats
23 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is 5α-DHP the same thing as allopregnanolone?
No. 5α-DHP (5α-pregnane-3,20-dione) sits one step upstream; 3α-hydroxysteroid dehydrogenase reduces its 3-keto group to make allopregnanolone. The two are readily interconverted, but they act differently: 5α-DHP works mainly through the nuclear progesterone receptor to control gene transcription, whereas allopregnanolone works mainly through the GABA-A receptor to produce fast inhibition.
Does 5α-DHP calm the brain the way allopregnanolone does?
Not directly. A 3α-hydroxyl group is required for a neurosteroid to potentiate the GABA-A receptor, and 5α-DHP lacks it. Its contribution to GABAergic calm is indirect, as the immediate precursor that the brain converts into allopregnanolone.
Can you take 5α-DHP as a supplement?
It is an endogenous steroid, not an approved or established supplement, and there is no validated human dose. Because it is a potent progesterone-receptor agonist and a breast-cell mitogen in the laboratory, it is treated as a research compound rather than a nootropic.
Why do horses matter for understanding 5α-DHP?
Pregnant mares lose detectable progesterone in the second half of gestation yet stay pregnant. Research showed that 5α-DHP is the hormone filling that role, activating the progesterone receptor as strongly as progesterone; this proved 5α-DHP is a biopotent progestogen in its own right, not merely an inactive intermediate.
What is 5α-DHP's link to stress and mood?
In socially isolated mice, brain 5α-DHP and allopregnanolone fall to roughly a third of normal, and antidepressants such as fluoxetine can restore the pathway. In humans, higher plasma 5α-DHP has been associated with depression in the latter half of pregnancy. The pathway is therefore of interest in mood research, though 5α-DHP itself is not a treatment.
Limitations of the evidence
- Not characterized for human supplemental use; no established safety margin or dosing
Adverse effects
- Promotes proliferation and metastatic behavior of breast cancer cells in laboratory models, independent of classical hormone-receptor status
- Elevated circulating levels are associated with depression in late pregnancy (association, not proven cause)
- As a potent progestogen, exogenous exposure would be expected to carry systemic progestational effects
- Brain levels fall under chronic stress and social isolation, a change linked to emotional and cognitive dysfunction in animal models